

FORM PTO-1390 MODIFIED	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	<div style="text-align: right;"> 19 JUL 2006 ATTORNEY'S DOCKET NUMBER 620-421 </div>
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) <div style="text-align: center;">10/570,487</div>
INTERNATIONAL APPLICATION NO. <div style="text-align: center;">PCT/GB2004/003854</div>	INTERNATIONAL FILING DATE <div style="text-align: center;">9 September 2004</div>	PRIORITY DATE CLAIMED <div style="text-align: center;">12 September 2003</div>
TITLE OF INVENTION <div style="text-align: center;">COMPOSITIONS COMPRISING A FRAGMENT OF THE HERPESVIRAL PROTEIN VP22 FOR DELIVERY OF SUBSTANCES TO CELLS</div>		
APPLICANT(S) FOR DO/EO/US <div style="text-align: center;">O'HARE ET AL.</div>		
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</p> <ol style="list-style-type: none"> 1. <input type="checkbox"/> This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. 2. <input checked="" type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input type="checkbox"/> The U.S. has been elected (Article 31). 5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (pages specification, claims & abstract (claims), sheets drawings). b. <input type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (pages specification, claims & abstract (claims), sheets drawings, page Certificate of Translation). b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). b. <input type="checkbox"/> Declaration was submitted to the International Bureau during International Phase (see copies of Declaration (page Form PCT/RO/101 and Form PCT/IB/371 and first page of printed publication acknowledging receipt thereof attached). 10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). <p>Items 11 To 20 below concern document(s) or information included:</p> <ol style="list-style-type: none"> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98. 12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included. 13. <ol style="list-style-type: none"> a. <input type="checkbox"/> A FIRST preliminary amendment. b. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> An Application Data Sheet under 37 C.F.R. § 1.76. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825. 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input checked="" type="checkbox"/> Other items or information. Amendment; Submission & copies of references listed on PTO-1449 Form filed 3/3/2006; paper & computer readable copies of Sequence Listing 		

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 10/570,487		INTERNATIONAL APPLICATION NO. PCT/GB2004/003854		ATTORNEY'S DOCKET NUMBER 620-421	
<input checked="" type="checkbox"/> The following fees are submitted:					
BASIC NATIONAL FEE (37 C.F.R. 1.492(a)(1)-(5):					
21. <input type="checkbox"/> Basic national fee				\$300.00 (1631)/\$150.00 (2631)	\$
22. <input type="checkbox"/> Examination Fee.....				\$0 (1643/2643)	
				\$200.00 (1633)/\$100.00 (2633)	\$
23. <input type="checkbox"/> Search Fee				\$0 (1640/2640)	
				\$100 (1641)/\$50 (2641)	
				\$400 (1642)/\$200 (2642)	
				\$500.00 (1632)/\$250.00 (2632)	\$
TOTAL OF ABOVE CALCULATIONS					\$ 0.00
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					
Total Sheets		Extra Sheets		Number of each additional 50 or fraction thereof (round up to a whole number)	
0 -100		0 /50 =		0.00	
				\$0.00 (1681)	
				\$0.00 (2681)	
Surcharge of \$130.00 (1617)/\$65.00 (2617) for furnishing the oath or declaration later than <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(e)).					
CLAIMS		NUMBER FILED		# EXTRA	
Total Claims		minus 20 =		0 X	
				\$50.00 (1615)/	
Independent Claims		minus 3 =		0 X	
				\$200.00 (1614)	
				\$100.00 (2614)	
MULTIPLE DEPENDENT CLAIMS(S) (if applicable)				\$360.00 (1616)/\$180.00 (2616)	
				\$ 0.00	
Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s): One Month Extension \$120.00 (1251)/\$60.00 (2251); Two Month Extensions \$450.00 (1252)/\$225.00 (2252); Three Month Extensions \$1020.00 (1253)/\$510.00 (2253); Four Month Extensions \$1590.00 (1254)/\$795.00 (2254)					
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.					
Processing fee of \$130.00 (1618), for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(f)).					
TOTAL NATIONAL FEE =					
\$ 0.00					
Fee for recording the enclosed assignment (37 C.F.R. 1.21(h). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. 3.28, 3.31). \$40.00 (8021) per property					
Fee for Petition to Revive Unintentionally Abandoned Application;\$1500.00 (1453) / \$750.00 (2453)					
TOTAL FEES ENCLOSED =					
\$ 40.00					
Amount to be refunded:					
\$					
Amount to be Charged:					
\$					

U.S. Application No.10/570,487; Atty Docket No.620-421

- a. ☒ A check in the amount of \$40.00 to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. 14-1140 in the amount of \$_____ to cover the above fees.
A duplicate copy of this form is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-1140. A duplicate copy of this form is enclosed.
- d. ☐ **CREDIT CARD PAYMENT FORM ATTACHED.**
- e. ☒ The entire content of International Application No. **PCT/GB2004/003854** and any U.S. and foreign application(s) corresponding thereto, and GB 0321311.3, referred to in this application is/are hereby incorporated by reference in this application.

NOTE: Where an appropriate time limit under 37 C.F.R. 1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. 1.137(a) or (b) must be filed and granted to restore the application to pending status.


CORRESPONDENCE ADDRESS

Direct all correspondence to:

☒ **Customer Number:****23117***Type Customer Number here*

Telephone: (703) 816-4000

BJS:pp


B. J. Sadoff

NAME

36,663

REGISTRATION NUMBER

July 19, 2006

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

O'HARE ET AL.

Atty. Ref.: 620-421

Serial No. 10/570,487

Group: Unknown

Filed: March 3, 2006

Examiner: Unknown

For: COMPOSITIONS COMPRISING A FRAGMENT OF THE HERPESVIRAL
PROTEIN VP22 FOR DELIVERY OF SUBSTANCES TO CELLS

* * * * *

July 19, 2006

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


SUBMISSION

Submitted herewith is a copy of the references listed on the PTO-1449 Form and in the International Search Report, copies of which were filed with the application on March 3, 2006. Return of an initialed copy of the PTO-1449 Form filed March 3, 2006, pursuant to MPEP Section 609, is requested.

Respectfully submitted,

NIXON & VANDERHYTE P.C.

By: _____


B. J. Sadoff
Reg. No. 36,663

BJS:pp
901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100